Retinoic acid as a novel medical therapy for Cushing's disease in dogs

Endocrinology

Volumn 147, Issue 9, 2006, Pages 4438-4444

  Castillo, Victor ^a   Giacomini, Damiana ^b   Páez Pereda, Marcelo ^c,d   Stalla, Johanna ^c   Labeur, Marta ^c   Theodoropoulou, Marily ^c   Holsboer, Florian ^c   Grossman, Ashley B ^e,g   Stalla, Günter K ^c   Arzt, Eduardo ^b,f  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INSTITUTO DE FISIOLOGÍA   (Argentina)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^d Affectis Pharmaceutical AG   (Germany)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^g ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; CORTICOTROPIN; CREATININE; HYDROCORTISONE; KETOCONAZOLE; RETINOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CREATININE URINE LEVEL; CUSHING DISEASE; DOG; DRUG EFFICACY; DRUG SAFETY; FEMALE; HORMONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOPHYSIS; HYPOPHYSIS ADENOMA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL; TUMOR VOLUME;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; ALPHA-MSH; ANIMALS; BODY WEIGHT; CREATININE; DOG DISEASES; DOGS; FEMALE; HYDROCORTISONE; KETOCONAZOLE; MAGNETIC RESONANCE IMAGING; MALE; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PITUITARY NEOPLASMS; SURVIVAL RATE; TRETINOIN;

EID: 33747623970     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0414     Document Type: Article

References (38)

1. Bevan JS, Webster J, Burke CW, Scanlon MF 1992 Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220-240
2. Bevan JS 2005 The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
3. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410
4. Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, van Koetsveld PM, Barreca A, De Caro ML, Lombardi G, Colao A, Lamberts SW, Hofland LJ 2004 Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab 89:4493-4502
5. Boscaro M, Barzon L, Fallo F, Sonino N 2001 Cushing's syndrome. Lancet 357:783-791
6. De Herder WW, Lamberts SW 1999 Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Postgrad Med J 75:65-66
7. Melmed S 2003 Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest 112:1603-1618
8. Dahia PL, Grossman AB 1999 The molecular pathogenesis of corticotroph tumors. Endocr Rev 20:136-155
9. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B, Lombardi G 2000 New medical approaches in pituitary adenomas. Horm Res 53(Suppl 3):76-87
10. Newell-Price J, Bertagna X, Grossman AB, Nieman LK 2006 Cushing's syndrome. Lancet 367:1605-1617
11. Newell-Price J, Trainer P, Besser M, Grossman A 1998 The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 19:647-672
12. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602
13. Nieman LK 2002 Medical therapy of Cushing's disease. Pituitary 5:77-82
14. Morris D, Grossman A 2002 The medical management of Cushing's syndrome. Ann NY Acad Sci 970:119-133
15. Heaney AP, Fernando M, Yong WH, Melmed S 2002 Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8:1281-1287
16. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, Chiodini I, Ferrero S, Trimarchi F, Arosio M, Beck-Peccoz P 2004 Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease. Eur J Endocrinol 151:173-178
17. Kurie JM 1999 The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol 11:497-502
18. Merino R, Hurle JM 2003 The molecular basis of retinoid action in tumors. Trends Mol Med 9:509-511
19. Lotan R 1996 Retinoids in cancer chemoprevention. FASEB J 10:1031-1039
20. Kang HJ, Song MR, Lee SK, Shin EC, Choi YH, Kim SJ, Lee JW, Lee MO 2000 Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid. Exp Cell Res 256:545-554
21. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP, Pfahl M 1994 A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 372:107-111
22. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F, Arzt E 2002 Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 16:1638-1651
23. Maira M, Martens C, Philips A, Drouin J 1999 Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 19:7549-7557
24. Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P, Drouin J 1997 Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 17:5946-5951
25. Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla GK 2001 Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 108:1123-1131
26. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, Mauceli E, Xie X, Breen M, Wayne RK, Ostrander EA, Ponting CP, Galibert F, Smith DR, Dejong PJ, Kirkness E, Alvarez P, Biagi T, Brockman W, Butler J, Chin CW, Cook A, Cuff J, Daly MJ, Decaprio D, Gnerre S, Grabherr M, Kellis M, Kleber M, Bardeleben C, Goodstadt L, Heger A, Hitte C, Kim L, Koepfli KP, Parker HG, Pollinger JP, Searle SM, Sutter NB, Thomas R, Webber C, Baldwin J, Abebe A, Abouelleil A, Aftuck L, Ait-Zahra M, Aldredge T, Allen N, An P, Anderson S, Antoine C, Arachchi H, Aslam A, Ayotte L, Bachantsang P, Barry A, Bayul T, Benamara M, Berlin A, Bessette D, Blitshteyn B, Bloom T, Blye J, Boguslavskiy L, Bonnet C, Boukhgalter B, Brown A, Cahill P, Calixte N, Camarata J, Cheshatsang Y, Chu J, Citroen M, Collymore A, Cooke P, Dawoe T, Daza R, Decktor K, Degray S, Dhargay N, Dooley K, Dorje P, Dorjee K, Dorris L, Duffey N, Dupes A, Egbiremolen O, Elong R, Falk J, Farina A, Faro S, Ferguson D, Ferreira P, Fisher S, Fitzgerald M, Foley K, Foley C, Franke A, Friedrich D, Gage D, Garber M, Gearin G, Giannoukos G, Goode T, Goyette A, Graham J, Grandbois E, Gyaltsen K, Hafez N, Hagopian D, Hagos B, Hall J, Healy C, Hegarty R, Honan T, Horn A, Houde N, Hughes L, Hunnicutt L, Husby M, Jester B, Jones C, Kamat A, Kanga B, Kells C, Khazanovich D, Kieu AC, Kisner P, Kumar M, Lance K, Landers T, Lara M, Lee W, Leger JP, Lennon N, Leuper L, Levine S, Liu J, Liu X, Lokyitsang Y, Lokyitsang T, Lui A, Macdonald J, Major J, Marabella R, Maru K, Matthews C, McDonough S, Mehta T, Meldrim J, Melnikov A, Meneus L, Mihalev A, Mihova T, Miller K, Mittelman R, Mlenga V, Mulrain L, Munson G, Navidi A, Naylor J, Nguyen T, Nguyen N, Nguyen C, Nicol R, Norbu N, Norbu C, Novod N, Nyima T, Olandt P, O'Neill B, O'Neill K, Osman S, Oyono L, Patti C, Perrin D, Phunkhang P, Pierre F, Priest M, Rachupka A, Raghuraman S, Rameau R, Ray V, Raymond C, Rege F, Rise C, Rogers J, Rogov P, Sahalie J, Settipalli S, Sharpe T, Shea T, Sheehan M, Sherpa N, Shi J, Shih D, Sloan J, Smith C, Sparrow T, Stalker J, Stange-Thomann N, Stavropoulos S, Stone C, Stone S, Sykes S, Tchuinga P, Tenzing P, Tesfaye S, Thoulutsang D, Thoulutsang Y, Topham K, Topping I, Tsamla T, Vassiliev H, Venkataraman V, Vo A, Wangchuk T, Wangdi T, Weiand M, Wilkinson J, Wilson A, Yadav S, Yang S, Yang X, Young G, Yu Q, Zainoun J, Zembek L, Zimmer A, Lander ES 2005 Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438:803-819
27. Ling GV, Stabenfeldt GH, Comer KM, Gribble DH, Schechter RD 1979 Canine hyperadrenocorticism: pretreatment clinical and laboratory evaluation of 117 cases. J Am Vet Med Assoc 174:1211-1215
28. Feldman EC, Bruyette DS, Nelson RW, Farver TB 1990 Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism. J Am Vet Med Assoc 197:71-78
29. Wei LN 2003 Retinoid receptors and their coregulators. Annu Rev Pharmacol Toxicol 43:47-72
30. Rijnberk A, van Wees A, Mol JA 1988 Assessment of two tests for the diagnosis of canine hyperadrenocorticism. Vet Rec 122:178-180
31. Orth DN, Peterson ME, Drucker WD 1988 Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Cushing's syndrome: diurnal rhythm and responses to various stimuli. Endocrinology 122:1250-1262
32. Muller OA, Stalla GK, von Werder K 1983 Corticotropin releasing factor: a new tool for the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 57:227-229
33. Bosje JT, Rijnberk A, Mol JA, Voorhout G, Kooistra HS 2002 Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism. Domest Anim Endocrinol 22:201-210
34. Tanaka S 2003 Comparative aspects of intracellular proteolytic processing of peptide hormone precursors: studies of proopiomelanocortin processing. Zoolog Sci 20:1183-1198
35. Ross EJ, Linch DC 1982 Cushing's syndrome - killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 2:646-649
36. Lado-Abeal J, Rodriguez-Arnao J, Newell-Price JD, Perry LA, Grossman AB, Besser GM, Trainer PJ 1998 Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels. J Clin Endocrinol Metab 83:3083-3088
37. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA 1993 Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 90:1440-1444
38. Beale EG, Hammer RE, Antoine B, Forest C 2004 Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene. Trends Endocrinol Metab 15:129-135